Stock Rating Report for GSK

Ticker: 

Stock Information

Ticker GSK
Company Name GlaxoSmithKline plc
Current Price $44.80
Previous Close $44.80
Industry Drug Manufacturers - Major
Sector HEALTHCARE
Long Stop Loss Members Only
Short Stop Loss Members Only
Expected Move Members Only
Optionable? Yes

StockProphet Ratings

Join today to see our Technical, Fundamental, and Composite Stock Rating for this stock.

Sector Risks

Sign up for MarketProphet today to see our 30, 60, and 90 day risk assessment for this stock.


Chart

We use technical analysis and fundamental analysis to recommend ratings for thousands of stocks. If you had a subscription, this space would show our 3 year history of trades for GSK. However, we only show it to our subscribers.

We update our ratings and stop losses EVERY WEEK.

Don't miss out on what we recommend for GlaxoSmithKline plc next week. Sign up today and start making money!

Demand Fundamentals

Demand Fundamental Value Score Rating
Qtr/Qtr Revenue Growth Members Only
Qtr/Qtr Earnings Growth Members Only
Year/Year Revenue Growth Members Only
Year/Year Earnings Growth Members Only
Multi-Year Revenue Growth Members Only
Multi-Year Earnings Growth Members Only
Relative PE Ranking Members Only
Return on Equity Members Only
Yield Members Only
Institutional Holding Members Only
Stock Price Members Only
Relative Fundamental Ranking Members Only
Total Score Members Only

Demand Technicals

Demand Technical Value Score Rating
Recommended Condition Members Only
Trading Zone Members Only
Average Trading Volume Members Only
Industry Bull/Bear Condition Members Only
Sector Bull/Bear Condition Members Only
Current Signal Start Date Members Only
Total Score Members Only

Company Profile

GlaxoSmithKline plc, together with its subsidiaries, engages in the discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health-related consumer products worldwide. It offers pharmaceutical products in various therapeutic areas comprising respiratory, HIV, central nervous system, anti-bacterials, metabolic, vaccines, oncology and emesis, cardiovascular and urogenital, and dermatologicals. The company provides prescription medicines to treat a range of conditions, including infections, depression, skin conditions, asthma, heart and circulatory disease, and cancer. It also markets approximately 30 vaccines to prevent life-threatening or crippling illnesses, such as hepatitis A, hepatitis B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza, and bacterial meningitis. In addition, the company provides OTC medicines, including Panadol, a paracetamol-based treatment of headache and joint pain, fever, and cold symptoms- Gaviscon, a range of antacid products that relieve heartburn due to acid reflux- alli, a weight loss product- and NicoDerm, NiQuitin CQ, Nicabate, and Nicorette for the treatment of nicotine withdrawal as an aid to quit smoking. Further, it offers oral healthcare products comprising Aquafresh, a range of toothpastes, toothbrushes, and mouthwashes- Sensodyne, a range of toothpastes and toothbrushes for the prevention of dental sensitivity- Biotene, a mouthwash and gel to treat dry mouth- and Polident, Poligrip, and Corega, which are denture adhesives and cleansers. Additionally, the company provides nutritional healthcare products consisting of Lucozade, an energy and sports drinks for energy and hydration- Horlicks, a malted, milk-based drink and food for nutrition application- and Ribena, a blackcurrant juice-based drink, as well as markets skincare products. GlaxoSmithKline plc was founded in 1999 and is headquartered in Brentford, United Kingdom.


Latest News

Wed, 08 Feb 2012 02:29:34 GMT[$$] Glaxo Has Been Repatriating Euro-Zone Cash Daily to U.K.
Tue, 07 Feb 2012 20:30:06 GMTGlaxoSmithKline plc's CEO Discusses Q4 2011 Results - Earnings Call Transcript
Tue, 07 Feb 2012 19:48:15 GMTSummary Box: GlaxoSmithKline swings to 4Q profit
Tue, 07 Feb 2012 17:43:03 GMTGlaxo Slips After Disappointing Earnings, Diabetes Drug Sales
Tue, 07 Feb 2012 17:39:00 GMTGlaxoSmithKline Swings To Profit But Shy Of Estimates
Tue, 07 Feb 2012 17:10:49 GMTEurope stock markets end mostly lower
Tue, 07 Feb 2012 16:33:00 GMTSiemens Forms New Companion Diagnostics Partnerships with ViiV Healthcare and Tocagen
Tue, 07 Feb 2012 16:28:00 GMT[video] Global Markets Update: Europe Still Waiting for Greece
Tue, 07 Feb 2012 16:21:30 GMTTo Outsource Or Not to Outsource? That's the Pharma R&D Question
Tue, 07 Feb 2012 16:15:00 GMT[video] GlaxoSmithKline CEO on Earnings
Tue, 07 Feb 2012 14:04:21 GMTForget Europe, U.S. Stocks Will Rise 10% This Year: Ablin
Tue, 07 Feb 2012 14:03:20 GMTGlaxoSmithKline back in profit in 4th quarter
Tue, 07 Feb 2012 13:57:44 GMTGreek Malaise Continues; Futures Slip Early
Tue, 07 Feb 2012 13:23:51 GMTStocks to Watch: Coca-Cola, BP (Update 1)
Tue, 07 Feb 2012 12:51:00 GMTGSK Upbeat on Solid Results - Interviews with CEO and CFO
Tue, 07 Feb 2012 10:30:44 GMT5 Defensive Stocks For A Very Volatile Market
Mon, 06 Feb 2012 21:52:01 GMT[$$] Merck to File Insomnia Drug Application
Mon, 06 Feb 2012 20:55:47 GMTGlaxoSmithKline 'finding' halts four trials of Anacor antibiotic
Mon, 06 Feb 2012 20:27:27 GMTProtecting Your Merck Investment
Mon, 06 Feb 2012 19:29:45 GMTMonday?s biggest gaining and declining stocks
News provided by Yahoo! Finance